Ignite Creation Date:
2025-12-24 @ 4:18 PM
Ignite Modification Date:
2025-12-28 @ 2:03 AM
Study NCT ID:
NCT03487666
Status:
COMPLETED
Last Update Posted:
2024-12-03
First Post:
2018-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Sponsor:
Georgetown University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2017-1535
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |